DK3286190T3 - Farmaceutiske saltformer af en inhibitor af semicarbazid-sensitiv aminoxidase (ssao) - Google Patents
Farmaceutiske saltformer af en inhibitor af semicarbazid-sensitiv aminoxidase (ssao) Download PDFInfo
- Publication number
- DK3286190T3 DK3286190T3 DK16719892.8T DK16719892T DK3286190T3 DK 3286190 T3 DK3286190 T3 DK 3286190T3 DK 16719892 T DK16719892 T DK 16719892T DK 3286190 T3 DK3286190 T3 DK 3286190T3
- Authority
- DK
- Denmark
- Prior art keywords
- aminoxidase
- semicarbazid
- ssao
- inhibitor
- sensitive
- Prior art date
Links
- 102100027159 Membrane primary amine oxidase Human genes 0.000 title 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507031.1A GB201507031D0 (en) | 2015-04-24 | 2015-04-24 | New pharmaceutical salt forms |
| PCT/GB2016/051119 WO2016170351A1 (en) | 2015-04-24 | 2016-04-22 | Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3286190T3 true DK3286190T3 (da) | 2020-07-13 |
Family
ID=53488629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16719892.8T DK3286190T3 (da) | 2015-04-24 | 2016-04-22 | Farmaceutiske saltformer af en inhibitor af semicarbazid-sensitiv aminoxidase (ssao) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10316034B2 (enExample) |
| EP (1) | EP3286190B1 (enExample) |
| JP (2) | JP2018513189A (enExample) |
| KR (1) | KR20170139045A (enExample) |
| CN (2) | CN107531702A (enExample) |
| AR (1) | AR104360A1 (enExample) |
| AU (1) | AU2016251707B2 (enExample) |
| BR (1) | BR112017020016A2 (enExample) |
| CA (1) | CA2979144A1 (enExample) |
| DK (1) | DK3286190T3 (enExample) |
| EA (1) | EA035668B1 (enExample) |
| ES (1) | ES2804155T3 (enExample) |
| GB (1) | GB201507031D0 (enExample) |
| HU (1) | HUE049985T2 (enExample) |
| IL (1) | IL254153A0 (enExample) |
| MX (1) | MX2017013049A (enExample) |
| PT (1) | PT3286190T (enExample) |
| SG (1) | SG11201707867WA (enExample) |
| WO (1) | WO2016170351A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| GB201618029D0 (en) | 2016-10-25 | 2016-12-07 | Proximagen Ltd | New process |
| CN108017634A (zh) * | 2017-12-15 | 2018-05-11 | 清华大学 | 一种制备吡咯并多环衍生物的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141899A (en) | 1976-01-07 | 1979-02-27 | Societa' Farmaceutici Italia S.P.A. | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives |
| IT1098015B (it) | 1978-08-07 | 1985-08-31 | Farmaceutici Italia | Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati |
| EP1173438A1 (en) * | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| SE0004101D0 (sv) | 2000-11-09 | 2000-11-09 | Pharmacia Ab | New use |
| AU2002214505A1 (en) | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
| CA2556914A1 (en) * | 2004-02-25 | 2005-09-09 | La Jolla Pharmaceutical Company | Amines and amides for the treatment of diseases |
| US20070066646A1 (en) | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
| EP2029164B1 (en) | 2006-06-07 | 2015-12-23 | The Board of Trustees of the Leland Stanford Junior University | Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
| JP5613671B2 (ja) * | 2008-09-16 | 2014-10-29 | プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． | 新規化合物ｉｉ |
| BRPI0918602B8 (pt) * | 2008-09-16 | 2021-05-25 | Benevolentai Cambridge Ltd | inibidores da atividade de ssao, seu uso, e formulação farmacêutica |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
| IN2014DN01883A (enExample) * | 2011-09-14 | 2015-05-15 | Proximagen Ltd | |
| GB201304526D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| HUE042625T2 (hu) | 2014-04-15 | 2019-07-29 | Pecsi Tudomanyegyetem | Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban |
| GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
-
2015
- 2015-04-24 GB GBGB1507031.1A patent/GB201507031D0/en not_active Ceased
-
2016
- 2016-04-22 JP JP2017555499A patent/JP2018513189A/ja active Pending
- 2016-04-22 EA EA201792121A patent/EA035668B1/ru not_active IP Right Cessation
- 2016-04-22 ES ES16719892T patent/ES2804155T3/es active Active
- 2016-04-22 KR KR1020177032022A patent/KR20170139045A/ko not_active Withdrawn
- 2016-04-22 CA CA2979144A patent/CA2979144A1/en not_active Abandoned
- 2016-04-22 EP EP16719892.8A patent/EP3286190B1/en active Active
- 2016-04-22 CN CN201680023326.3A patent/CN107531702A/zh active Pending
- 2016-04-22 SG SG11201707867WA patent/SG11201707867WA/en unknown
- 2016-04-22 AU AU2016251707A patent/AU2016251707B2/en not_active Ceased
- 2016-04-22 DK DK16719892.8T patent/DK3286190T3/da active
- 2016-04-22 WO PCT/GB2016/051119 patent/WO2016170351A1/en not_active Ceased
- 2016-04-22 BR BR112017020016A patent/BR112017020016A2/pt not_active IP Right Cessation
- 2016-04-22 US US15/567,536 patent/US10316034B2/en active Active
- 2016-04-22 PT PT167198928T patent/PT3286190T/pt unknown
- 2016-04-22 AR ARP160101126A patent/AR104360A1/es unknown
- 2016-04-22 MX MX2017013049A patent/MX2017013049A/es unknown
- 2016-04-22 HU HUE16719892A patent/HUE049985T2/hu unknown
- 2016-04-22 CN CN202110072000.2A patent/CN112851669A/zh active Pending
-
2017
- 2017-08-24 IL IL254153A patent/IL254153A0/en unknown
-
2021
- 2021-01-28 JP JP2021012044A patent/JP2021073256A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL254153A0 (en) | 2017-10-31 |
| HK1249906A1 (en) | 2018-11-16 |
| US10316034B2 (en) | 2019-06-11 |
| SG11201707867WA (en) | 2017-11-29 |
| AU2016251707B2 (en) | 2020-02-20 |
| MX2017013049A (es) | 2017-12-08 |
| JP2018513189A (ja) | 2018-05-24 |
| GB201507031D0 (en) | 2015-06-10 |
| EA201792121A1 (ru) | 2018-03-30 |
| EA035668B1 (ru) | 2020-07-23 |
| CN112851669A (zh) | 2021-05-28 |
| BR112017020016A2 (pt) | 2018-06-19 |
| US20180111928A1 (en) | 2018-04-26 |
| EP3286190B1 (en) | 2020-06-03 |
| CA2979144A1 (en) | 2016-10-27 |
| HUE049985T2 (hu) | 2020-11-30 |
| WO2016170351A1 (en) | 2016-10-27 |
| AR104360A1 (es) | 2017-07-12 |
| JP2021073256A (ja) | 2021-05-13 |
| CN107531702A (zh) | 2018-01-02 |
| ES2804155T3 (es) | 2021-02-04 |
| AU2016251707A1 (en) | 2017-10-05 |
| EP3286190A1 (en) | 2018-02-28 |
| PT3286190T (pt) | 2020-07-09 |
| KR20170139045A (ko) | 2017-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2025044I1 (no) | Inavolisib or a pharmaceutically acceptable salt thereof | |
| NO2021035I1 (no) | Risdiplam or a pharmaceutically acceptable salt thereof | |
| IL269812A (en) | Ferroportin-inhibitor salts | |
| NO2022058I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
| FIC20240006I1 (fi) | Gefapiksantti tai sen farmaseuttisesti hyväksyttävä suola | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| HUE054474T2 (hu) | USP30 inhibitor 1-ciano-pirrolidin vegyületek | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| LT3137169T (lt) | Lizinui specifinės demetilazės-1 inhibitoriai | |
| HUE047477T2 (hu) | Palbociclib szilárd dózisformái | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| DK3822855T3 (da) | Rumlig positionering af offshorestrukturer | |
| SI3529248T1 (sl) | Farmacevtske spojine | |
| LT3319959T (lt) | Histono deacetilazės hetero-halogeno inhibitoriai | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| IL254779A0 (en) | Methods of administering glutaminase inhibitors | |
| BR112017000042A2 (pt) | inibidores de desmetilase-1 lisina-específica | |
| DK3313833T3 (da) | Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase | |
| DK3204398T3 (da) | Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer | |
| DK3529240T3 (da) | Farmaceutiske forbindelser | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3390422T3 (da) | Krystalformer af lnt |